Genetic and protein profiling in patients with oesophageal cancer
- Conditions
- oesophageal canceroesophageal neoplasm1001799010017998
- Registration Number
- NL-OMON32169
- Lead Sponsor
- ederlands Kanker Instituut
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 80
Inclusion Criteria
1) Patients presenting at the NKI-AvL or LUMC for the treatment of oesophageal cancer.
2) Planned gastroduodenoscopy (for diagnosis, feeding tube insertion, dilatation, etc.) or endoscopic ultrasonography (for staging).
3) No evidence of distant metastases at presentation (by endoscopic ultrasonography, computer tomography, and positron emission tomography)
4) Able and willing to undergo tissue sampling for tumour genetic analyses.
5) Age > 18 years.
Exclusion Criteria
1) Any condition that prohibits safe biopsy sampling (e.g. use of anticoagulants).
2) Incapacity or unwillingness to give written informed consent.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The following comparisons will be performed:<br /><br>1) Patients who are diagnosed with metastatic disease within 1 year after<br /><br>diagnosis versus patients without metastatic disease within 1 year after<br /><br>diagnosis.<br /><br>2) Patients in whom the tumour shows response to preoperative or<br /><br>definitive(chemo)radiotherapy versus patients in whom the tumour is<br /><br>unresponsive to this type of treatment.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Not applicable</p><br>